Publications by authors named "Thomas Otten"

Claim this Profile
U
Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor-associated acute interstitial nephritis.
Shruti Gupta, Kavita Mistry, Firasat M Alikhan, Sherley M Mejia, Sagar Sadarangani, Thomas J Otten

Kidney Int· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Forecasting the value of innovation in total knee arthroplasty care: A headroom approach.
Thomas M Otten, Sabine E Grimm, Bram Ramaekers, Alex Roth, Pieter Emans

J Exp Orthop· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective.
Bradley M Sugden, Sabine E Grimm, Robert Wolff, Nigel Armstrong, Thomas Otten

Pharmacoeconomics· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Thomas Otten, Rob Riemsma, Ben Wijnen, Nigel Armstrong, Lisa Stirk

Pharmacoeconomics· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Willem Witlox, Sabine Grimm, Jeremy Howick, Nigel Armstrong, Charlotte Ahmadu, Thomas Otten

Pharmacoeconomics· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations.
Thomas Michael Otten, Sabine E Grimm, Bram Ramaekers, Manuela A Joore

Pharmacoeconomics· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Headroom Analysis for Early Economic Evaluation: A Systematic Review.
Esther A Boudewijns, Thomas M Otten, Mariam Gobianidze, Bram L Ramaekers, Onno C P van Schayck

Appl Health Econ Health Policy· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ben Wijnen, Willem Witlox, Robert Wolff, Debra Fayter, Bram Ramaekers, Thomas Otten

Pharmacoeconomics· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Thomas Otten, Rob Riemsma, Ben Wijnen, Nigel Armstrong, Lisa Stirk

Pharmacoeconomics· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finding the way forward: COVID-19 vaccination progress in Germany, Austria and Switzerland.
Zachary Desson, Lukas Kauer, Thomas Otten, Jan Willem Peters, Francesco Paolucci

Health Policy Technol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
State of the ART? Two New Tools for Risk Communication in Health Technology Assessments.
Sabine E Grimm, Xavier Pouwels, Bram L T Ramaekers, Ben Wijnen, Thomas Otten

Pharmacoeconomics· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 pandemic in the United States.
Savannah Bergquist, Thomas Otten, Nick Sarich

Health Policy Technol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis